Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer

REFERENCES

• Ocana A and Pandiella A: Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res 14, 961–970, 2008.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182, 1987.
   PubMed Web of Science ®Google Scholar
• Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, et al.: Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101, 107–113, 2009.
   PubMed Web of Science ®Google Scholar
• Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, et al.: Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A 97, 9609–9614, 2000.
   PubMed Web of Science ®Google Scholar
• Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, et al.: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178–182, 1987.
   PubMed Web of Science ®Google Scholar
• Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23, 2445–2459, 2005.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, et al.: Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9, 16–32, 2012.
   PubMed Web of Science ®Google Scholar
• Moy B and Goss PE: Lapatinib: current status and future directions in breast cancer. Oncologist 11, 1047–1057, 2006.
   PubMed Web of Science ®Google Scholar
• Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, et al.: Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55, 1186–1195, 2003.
   PubMed Web of Science ®Google Scholar
• Azim HA and Azim HA, Jr.: Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncol 8, 135–144, 2012.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66, 1630–1639, 2006.
   PubMed Web of Science ®Google Scholar
• Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, et al.: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24, 6213–6221, 2005.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, Im SA, Hegg R, et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366, 109–119, 2012.
   PubMed Web of Science ®Google Scholar
• Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, et al.: Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med 2, 211–230, 2010.
   PubMed Web of Science ®Google Scholar
• Preston TJ, Muller WJ, and Singh G: Scavenging of extracellular H2O2 by catalase inhibits the proliferation of HER-2/Neu-transformed rat-1 fibroblasts through the induction of a stress response. J Biol Chem 276, 9558–9564, 2001.
   PubMed Web of Science ®Google Scholar
• Wang XF, Witting PK, Salvatore BA, and Neuzil J: Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun 326, 282–289, 2005.
   PubMed Web of Science ®Google Scholar
• Yang CS, Chung JY, Yang G, Chhabra SK, and Lee MJ: Tea and tea polyphenols in cancer prevention. J Nutr 130, 472S–478S, 2000.
   PubMed Web of Science ®Google Scholar
• Lamson DW and Brignall MS: Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 4, 304–329, 1999.
   PubMedGoogle Scholar
• Khaw KT, Bingham S, Welch A, Luben R, Wareham N, et al.: Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 357, 657–663, 2001.
   PubMed Web of Science ®Google Scholar
• Hollman PC, Feskens EJ, and Katan MB: Tea flavonols in cardiovascular disease and cancer epidemiology. Proc Soc Exp Biol Med 220, 198–202, 1999.
   PubMed Web of Science ®Google Scholar
• Liu L, Hudgins WR, Shack S, Yin MQ, and Samid D: Cinnamic acid: a natural product with potential use in cancer intervention. Int J Cancer 62, 345–350, 1995.
   PubMed Web of Science ®Google Scholar
• Gomez EV, Perez YM, Sanchez HV, Forment GR, Soler EA, et al.: Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol 16, 2638–2647, 2010.
   PubMed Web of Science ®Google Scholar
• Dayem Uddin MAI, Mahmood I, Ghosha AK, and Khatuns RA: Findings of the 3-month supportive treatment with ocoxin solution beside the standard modalities of patients with different neoplastic diseases. TAJ 22, 172–175, 2009.
   Google Scholar
• Catania A, Barrajon-Catalan E, Nicolosi S, Cicirata F, and Micol V: Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res Treat 141, 55–65, 2013.
   PubMed Web of Science ®Google Scholar
• Seo HS, Choi HS, Choi HS, Choi YK, Um JY, et al.: Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells. Anticancer Res 31, 3301–3313, 2011.
   PubMed Web of Science ®Google Scholar
• Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, et al.: Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 22, 270–285, 2002.
   PubMed Web of Science ®Google Scholar
• de Alava E, Ocana A, Abad M, Montero JC, Esparis-Ogando A, et al.: Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 25, 2656–2663, 2007.
   PubMed Web of Science ®Google Scholar
• Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248–254, 1976.
   PubMed Web of Science ®Google Scholar
• Cabrera N, Diaz-Rodriguez E, Becker E, Martin-Zanca D, and Pandiella A: TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J Cell Biol 132, 427–436, 1996.
   PubMed Web of Science ®Google Scholar
• Kraus MH, Popescu NC, Amsbaugh SC, and King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J 6, 605–610, 1987.
   PubMed Web of Science ®Google Scholar
• Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, et al.: Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4, e5565, 2009.
   PubMed Web of Science ®Google Scholar
• Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, et al.: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89, 10578–10582, 1992.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, et al.: Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16, 1093–1107, 2009.
   PubMed Web of Science ®Google Scholar
• Burma S, Chen BP, Murphy M, Kurimasa A, and Chen DJ: ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276, 42462–42467, 2001.
   PubMed Web of Science ®Google Scholar
• Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell 116, 205–219, 2004.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, and Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22, 659–661, 2008.
   PubMed Web of Science ®Google Scholar
• Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, et al.: ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol 22, 2204–2219, 2002.
   PubMed Web of Science ®Google Scholar
• Tong W and Pollard JW: Genetic evidence for the interactions of cyclin D1 and p27(Kip1) in mice. Mol Cell Biol 21, 1319–1328, 2001.
   PubMed Web of Science ®Google Scholar
• Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, et al.: Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci U S A 98, 194–199, 2001.
   PubMed Web of Science ®Google Scholar
• Harper JW and Elledge SJ: The DNA damage response: ten years after. Mol Cell 28, 739–745, 2007.
   PubMed Web of Science ®Google Scholar
• Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, et al.: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20, 3210–3223, 2000.
   PubMed Web of Science ®Google Scholar